Danish biotechnology company Genmab has announced top line results from the Phase III EPCORE DLBCL-1 trial, highlighting improved progression-free survival (PFS) for its subcutaneous bispecific ...

Epkinly monotherapy significantly improved progression-free survival in relapsed/refractory DLBCL patients, reducing cancer ...

Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...

Topline results show that epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an improvement in PFS in patients receiving epcoritamab monotherapy (HR, 0.74; 95 ...

Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...

Genmab (GMAB) on Friday announced that its bispecific antibody epcoritamab, marketed as Epkinly in partnership with AbbVie ...

Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency ...

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from a debate at Lymphoma, Leukemia & Myeloma ...

Raskin, D-Maryland, said in a statement that “After several days of tests, I have been diagnosed with Diffuse Large B Cell Lymphoma, which is a serious but curable form of cancer. “I am about to ...

Please provide your email address to receive an email when new articles are posted on . Ryan: The field of diffuse large B-cell lymphoma has seen tremendous advancements in the recent years, and that ...

AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...